Alkermes ALKS

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.28 (-0.81%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Alkermes (ALKS)
    Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $34.35

    • Market Cap

      $5.59 Billion

    • Price-Earnings Ratio

      -32.10

    • Total Outstanding Shares

      162.61 Million Shares

    • Total Employees

      1,800

    • Dividend

      No dividend

    • IPO Date

      July 16, 1991

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      Connaught house, Dublin 4, L2, 00000

    • Homepage

      https://www.alkermes.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow From Operating Activities, Continuing$-47.77 Million
    Net Cash Flow, Continuing$-47.87 Million
    Net Cash Flow From Financing Activities, Continuing$-59,000
    Net Cash Flow From Investing Activities$-43,000
    Net Cash Flow From Financing Activities$-59,000
    Net Cash Flow From Operating Activities$-47.77 Million

    Income Statement

    October 1, 2024 to December 31, 2024
    MetricValue
    Other Operating Expenses$16.85 Million
    Operating Income/Loss$-64.90 Million
    Net Income/Loss Available To Common Stockholders, Basic$-57.96 Million
    Interest Income/Expense After Provision For Losses$5.39 Million
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Income Tax Expense/Benefit$-1.54 Million

    Comprehensive Income

    October 1, 2024 to December 31, 2024
    MetricValue
    Other Comprehensive Income/Loss$0
    Comprehensive Income/Loss$-57.96 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss Attributable To Parent$-57.96 Million

    Balance Sheet

    October 1, 2024 to December 31, 2024
    MetricValue
    Noncurrent Assets$61.70 Million
    Wages$14.47 Million
    Liabilities$60.18 Million
    Noncurrent Liabilities$11.68 Million
    Other Current Liabilities$26.26 Million
    Other Non-current Assets$58.62 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ALKS from trusted financial sources

      Related Companies

      Additional publicly traded companies similar to Alkermes (ALKS)
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.